ライフサイエンスコーパス: immunodeficient

1 e engrafted into neonatal mice that are both immunodeficient and deficient for myelin basic protein.

2 ve transfer of diabetes by CD4(+) T cells to immunodeficient and diabetes-resistant NOD.scid mice was

3 required to sustain enhanced tumor growth in immunodeficient and in immunocompetent mice.

4 glial progenitor cells (GPCs) into neonatal immunodeficient and myelin-deficient mice.

5 Notably, even immunodeficient and older mice were protected by this me

6 r stromal interaction molecule 1 (STIM1) are immunodeficient and prone to chronic infection by variou

7 ACs were transplanted into adrenalectomized, immunodeficient, and immunocompetent rats.

8 tence of TIL after adoptive transfer into an immunodeficient animal model and augments antitumor immu

9 rounds as a model, we show that ticks fed on immunodeficient animals demonstrate decreased fibrinogen

10 dation product) were evident in ticks fed on immunodeficient animals in comparison to ticks fed on im

11 orgement weights were noted for ticks fed on immunodeficient animals in comparison to ticks fed on im

12 ransfer of B cells from immunized animals to immunodeficient animals.

13 able levels, and are rapidly cleared even in immunodeficient animals.

14 .v. into antigen-positive, antigen-negative, immunodeficient, antigen-blocked, and antigen-depleted m

15 syringae strains into virulent pathogens in immunodeficient Arabidopsis thaliana under high humidity

16 activity in immunocompetent C57BL/6 but not immunodeficient athymic mice, leading to specific immune

17 ngerhans into the renal subcapsular space of immunodeficient BALB/c.rag2(-/-).cgamma(-/-) mice, previ

18 RAG2/IL2RG deficient pigs were immunodeficient, characterized by depletion of lymphocyt

19 Humanized nonobese diabetic severe combined immunodeficient common gamma chain-deficient stem cell f

20 e' whereby monogenic mutations cause primary immunodeficient conditions characterised by impaired imm

21 ncer cells are orthotopically implanted into immunodeficient consomic strains and tumor metrics are q

22 lycemia in nonobese diabetic/severe combined immunodeficient diabetic recipients was assessed.

23 s is shown to be limited and dependent on an immunodeficient experimental setting that is arguably of

24 Nonobese diabetic severe combined immunodeficient gammac(-/-) (NSG) mice received intraper

25 These results suggest that GE immunodeficient gnotobiotic pigs serve as a novel model

26 was attenuated in C57BL/6 wild-type mice and immunodeficient gp91(-/-) phox mice and was effective as

27 n Toll-like receptor signaling, are severely immunodeficient, highlighting the paramount role of IRAK

28 hindlimbs of NOD-Rag1(null) IL2rgamma(null) immunodeficient host mice regenerate new vascularized an

29 ansformed by E1A/Ras and generated tumors in immunodeficient hosts as efficiently as wild-type (WT) t

30 On retransplantation into immunodeficient hosts engrafted with human T cells, pane

31 a protocol to engineer humanized bone within immunodeficient hosts, which can be adapted to study the

32 ctions caused by viable vaccine organisms in immunodeficient hosts.

33 nd persist longer after adoptive transfer in immunodeficient human TPO-transgenic mice.

34 elanoma growth in immunocompetent but not in immunodeficient (IFNgamma(-/-), nude, or CD8(-/-)) mice.

35 tes to these disappointing outcomes using an immunodeficient IL2 receptor gamma (IL2rgamma)-null mous

36 /-)) Ag-specific Tfh cells were used to help immunodeficient Il21r(-/-) B cells following T-dependent

37 ontrast to nonobese diabetic severe combined immunodeficient Il2rg(-/-) (NSG) mice, human NK cells in

38 In fact, patients immunodeficient in genes in the IL-12, IL-23/IFN-gamma p

39 Immunodeficient individuals who excrete vaccine-derived

40 munity to C. difficile could be generated in immunodeficient individuals, we infected CD4(-/-) mice a

41 a (KS), a vascular tumor frequently found in immunodeficient individuals.

42 n inhibited ERalpha(+) cell tumorigenesis in immunodeficient mice ( approximately 66% reduction in tu

43 hen injected into the infarct border zone of immunodeficient mice 1 week after myocardial infarction,

44 superior expansion capacity in vitro and in immunodeficient mice and induced a superior antitumor ef

45 compared to lipid after transplantation into immunodeficient mice and led to a higher number of mural

46 ed purified human HSCs from MDS samples into immunodeficient mice and show that HSCs are the disease-

47 Immunodeficient mice are now readily engrafted with huma

48 s were transplanted under the KC of diabetic immunodeficient mice at a marginal dose (500 islet equiv

49 T1D, we developed a viral infection model in immunodeficient mice bearing human islet grafts.

50 ies, and CTLA4(apt)-STAT3 siRNA treatment of immunodeficient mice bearing human T cell lymphomas prom

51 Since the description of immunodeficient mice bearing mutations in the IL2 recept

52 In severe combined immunodeficient mice bearing SKOV3 tumors, 7 was efficac

53 mal imaging was performed in severe combined immunodeficient mice bearing solid and disseminated MM t

54 PV1/MusPV1) induces persistent papillomas in immunodeficient mice but not in common laboratory strain

55 tion of AML stem cells capable of engrafting immunodeficient mice by chemotherapeutic agents.

56 eate primary gastrointestinal (GI) tumors in immunodeficient mice by tail-vein injection rather than

57 In addition, attempts were made to infect immunodeficient mice by tick bite or inoculation of tick

58 Immunodeficient mice carrying a human SIRPA transgene ha

59 ability of the cells to long-term repopulate immunodeficient mice compared with equivalent input numb

60 e imaging of CTS transplanted onto hearts of immunodeficient mice demonstrated survival of </=30% of

61 AIRE levels in human thymus grafted in immunodeficient mice depended upon the sex of the recipi

62 Administering REGN421 to immunodeficient mice engineered to express human Dll4 in

63 Immunodeficient mice engrafted with either normal or can

64 Immunodeficient mice engrafted with functional human cel

65 Patient-derived xenograft tumours growing in immunodeficient mice exhibited enhanced hypoxia compared

66 MCC tumors implanted into immunodeficient mice failed to grow unless human T cells

67 Intrabone marrow transplantation into immunodeficient mice further showed that MA4 and KRAS(G1

68 ited by 3'3'-cGAMP injection in syngeneic or immunodeficient mice grafted with multiple myeloma.

69 Cell transplantation into immunodeficient mice has revolutionized our understandin

70 Immunodeficient mice have been used predominantly in bio

71 and significantly prolonged the survival of immunodeficient mice implanted with the transformed HCD-

72 ochetes occurred in both immunocompetent and immunodeficient mice in a manner indistinguishable from

73 T cell activation when used to reconstitute immunodeficient mice in the presence of scurfy fetal liv

74 arrow aspirates and were s.c. implanted into immunodeficient mice in the presence or absence of cord

75 progenitor cells and reduced their growth in immunodeficient mice in vivo, in comparison with NIL alo

76 ells infected with a LMP1-deficient EBV into immunodeficient mice induces B cell lymphomas.

77 from the brain when transferred to infected immunodeficient mice lacking T cells.

78 Nonobese diabetic severe combined immunodeficient mice lacking the cytokine receptor commo

79 (+) hematopoietic stem/progenitor cells into immunodeficient mice leads to robust reconstitution of h

80 of CD4(+)CD45RB(hi)Nlrp12(-/-) T cells into immunodeficient mice led to more severe colitis and atop

81 landular transplantation of cultured MSCs in immunodeficient mice led to their engraftment in the inj

82 eekly injections of 1 mg kg(-1) of mRNA into immunodeficient mice maintain trough VRC01 levels above

83 orted that reconstitution of CD3+ T cells in immunodeficient mice mimics ART-induced bone loss observ

84 have focused on the historic development of immunodeficient mice over the last 2 decades, as well as

85 ers as fetal human thymus (HU THY) grafts in immunodeficient mice receiving the same human CD34(+) ce

86 had approximately equal abilities to infect immunodeficient mice reconstituted with a human hematopo

87 Immunodeficient mice reconstituted with a human immune s

88 in human cancer cell lines xenografted into immunodeficient mice resulted in activation of canonical

89 PM-ALK-transformed CD4(+) T lymphocytes into immunodeficient mice resulted in formation of tumors ind

90 ent of human GPCs in normally myelinated and immunodeficient mice resulted in humanized white matter

91 antation of transduced FA CD34(+) cells into immunodeficient mice resulted in reproducible engraftmen

92 le fiber fragments into irradiated muscle of immunodeficient mice resulted in robust engraftment, mus

93 Transplantation of CYTH1-knockdown cells to immunodeficient mice resulted in significantly lower lon

94 c implant of CCA human cells in the liver of immunodeficient mice resulted in the release to serum of

95 e seminiferous tubules of germ cell-depleted immunodeficient mice revealed divergent fates of iPSCs p

96 Human islets transplanted into diabetic immunodeficient mice reversed diabetes but were rejected

97 alp hair follicles onto chemotherapy-treated immunodeficient mice serves as an excellent in vivo mode

98 n of day 20 CMs into the infarcted hearts of immunodeficient mice showed good engraftment, and echoca

99 Studies with immunodeficient mice showed that the mouse genetic backg

100 Xenografts assays in immunodeficient mice showed that the tumors generated by

101 Immunodeficient mice such as NOD-Rag1-/-IL2RgammaC-null

102 gical tolerance unfold in mutant mice and in immunodeficient mice that received p53cKO-derived thymoc

103 was induced in human arteries engrafted into immunodeficient mice that were reconstituted with T cell

104 l of s.c. human tumor xenografts in severely immunodeficient mice to assess the antitumor efficacy of

105 esponse of human hair follicles grafted onto immunodeficient mice to cyclophosphamide resembles the k

106 t diseases, followed by transplantation into immunodeficient mice to generate genetic models of clona

107 eight participants were then inoculated into immunodeficient mice to test for infectivity.

108 These models generally consist of immunodeficient mice transplanted with human cells or re

109 y positron emission tomography as well as in immunodeficient mice transplanted with human islets unde

110 nt donor cells were significantly reduced in immunodeficient mice transplanted with MF CD34(+) cell g

111 Immunodeficient mice transplanted with myelofibrosis pat

112 Human lymphocytes transferred into immunodeficient mice underwent activation and redistribu

113 r radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-

114 g effect of hypoxia on tumor initiation into immunodeficient mice using human non-small lung carcinom

115 Female severe combined immunodeficient mice were fed a low-fat/no-cholesterol d

116 M21 (human melanoma)-bearing severe combined immunodeficient mice were used for biodistribution, PET

117 ions of humanized mice generated in severely immunodeficient mice with a targeted disruption of the I

118 monstrated in human CD46 transgenic mice and immunodeficient mice with engrafted human CD34(+) cells

119 n the spinal cord and dorsal root ganglia of immunodeficient mice with higher efficacy than AAV2, 5,

120 Attempts to superinfect different types of immunodeficient mice with homologous B. burgdorferi indi

121 third model was generated by reconstituting immunodeficient mice with human CD34+ hematopoietic stem

122 Supplementation of immunodeficient mice with human RBCs supports infection

123 slow tumor progression when administered to immunodeficient mice with intracranial human glioma xeno

124 kinase plasminogen activator-severe combined immunodeficient mice with livers repopulated with human

125 n HD glial chimeras by neonatally engrafting immunodeficient mice with mutant huntingtin (mHTT)-expre

126 Severe combined immunodeficient mice xenografted with M21 human melanoma

127 metastasis, and mortality of severe combined immunodeficient mice xenografted with PC3 or DU145 cells

128 HSCs with >6-month repopulating activity in immunodeficient mice) displayed rapid increases in activ

129 ter xenotransplantation into severe-combined-immunodeficient mice, (3) expression of platelet-derived

130 d human TECs, human thymic tissue grafted to immunodeficient mice, and murine fetal thymus organ cult

131 sduced BM CD34+ cells were transplanted into immunodeficient mice, and the human cells recovered afte

132 ient-derived RCC samples into the kidneys of immunodeficient mice, as well as the s.c. implantation f

133 rs and transplanted them into hyperglycemic, immunodeficient mice, beta cell replication increased mo

134 as well as their efficiency in repopulating immunodeficient mice, both in the presence and absence o

135 However, in immunodeficient mice, deficiency of DbpA/B did not signi

136 antitumor activity in immunocompetent versus immunodeficient mice, demonstrating a contribution of th

137 When transplanted into immunodeficient mice, FOXP3-expressing HSC showed signif

138 When transplanted in immunodeficient mice, gene-modified naive-derived T(SCM)

139 myeloid cells in vitro and can also engraft immunodeficient mice, generating myeloerythoid and B-lym

140 Upon transplantation in immunodeficient mice, grafted cells form vascularized is

141 studying human malignant and normal HSCs in immunodeficient mice, including newly developed mice for

142 euroblastoma tumor engraftment and growth in immunodeficient mice, indicating an effect independent o

143 When xenografted into the cerebellum of immunodeficient mice, medulloblastoma cells with stable

144 tation of miR-377 silenced hCD34(+) cells in immunodeficient mice, promoting neovascularization (at 2

145 Following injection into immunodeficient mice, signals from gold-labeled human Mr

146 upon xenograft transplantation of cells into immunodeficient mice, the dominant-negative GRK2-K220R o

147 ransduced with the oncogene combination into immunodeficient mice, we generate a fatal B malignancy w

148 n of vascularized condensed progenitors into immunodeficient mice, we used an intravital imaging appr

149 ong-term reconstitution when transplanted in immunodeficient mice, were present in the chorion from 1

150 andates awareness of replicating MuLV in NOD immunodeficient mice, which can significantly influence

151 erformed in tumour xenografts in 15 NCr nude immunodeficient mice, which were treated with either the

152 P) effectively suppresses PEL progression in immunodeficient mice.

153 ard H460 tumor xenografts in severe-combined immunodeficient mice.

154 to high titers in cultured cell lines and in immunodeficient mice.

155 as potentiates their tumorigenic activity in immunodeficient mice.

156 ity and promoted malignant transformation in immunodeficient mice.

157 ect and grow in the tissues of wild-type and immunodeficient mice.

158 outgrowth of human multiple myeloma cells in immunodeficient mice.

159 d lineages and engraft primary and secondary immunodeficient mice.

160 nced EMT and CSC markers and tumor growth in immunodeficient mice.

161 diac repair and function after I-R injury in immunodeficient mice.

162 Kidneys were orthotopically allografted to immunodeficient mice.

163 d state in stroma coculture and engrafted in immunodeficient mice.

164 imary and metastatic human breast cancers in immunodeficient mice.

165 of genetically corrected patient cells into immunodeficient mice.

166 l of glycerol-induced AKI in severe combined immunodeficient mice.

167 t are defined by their ability to engraft in immunodeficient mice.

168 dependent gut inflammation in PBMC-engrafted immunodeficient mice.

169 autologous transplantation or infusion into immunodeficient mice.

170 rofiles and generate intracranial tumours in immunodeficient mice.

171 effector clones capable of engraftment into immunodeficient mice.

172 ion and in vivo tumors after xenografting in immunodeficient mice.

173 somes and CLL cells promoted tumor growth in immunodeficient mice.

174 mor-initiating capacity of ALDH(hi) cells in immunodeficient mice.

175 elanoma cells injected intracutaneously into immunodeficient mice.

176 CIK cells delayed autologous tumor growth in immunodeficient mice.

177 y, and tumorigenicity following injection in immunodeficient mice.

178 e treated with AZD1480 and transplanted into immunodeficient mice.

179 eled human regulatory macrophages (Mregs) in immunodeficient mice.

180 r orthotopic transplantation in the ovary of immunodeficient mice.

181 sel formation in vivo when transplanted into immunodeficient mice.

182 th rates of BCSC-derived tumor xenografts in immunodeficient mice.

183 induced by the transfer of human T cells in immunodeficient mice.

184 ured adult nonobese diabetic-severe combined immunodeficient mice.

185 been shown to prevent or reduce arthritis in immunodeficient mice.

186 d T cells (CART123) eradicate primary AML in immunodeficient mice.

187 r spheroids in vitro and generated tumors in immunodeficient mice.

188 lices and were implanted subcutaneously into immunodeficient mice.

189 n cancer cells is a xenotransplantation into immunodeficient mice.

190 properties and favored tumor development in immunodeficient mice.

191 nes showed variable engraftment potential in immunodeficient mice.

192 cells and failure to establish leukaemia in immunodeficient mice.

193 ated in PC-3 tumor-bearing severely combined immunodeficient mice.

194 ted intratibially in C3H and severe-combined immunodeficient mice.

195 zation in tail vein injection experiments in immunodeficient mice.

196 can sustain long-term thymopoiesis in ZAP-70-immunodeficient mice.

197 nt hematopoietic progenitors able to engraft immunodeficient mice.

198 ike particles in vitro and when infused into immunodeficient mice.

199 glial progenitor cells (GPCs) into neonatal immunodeficient mice.

200 a human immune system when transplanted into immunodeficient mice.

201 was able to spread intrahepatically and kill immunodeficient mice.

202 w recovery and muscular arteriole density in immunodeficient mice.

203 metastatic potential of MDA-MB-231 cells in immunodeficient mice.

204 f leukemia in NOD-SCID IL2Rgamma(null) (NSG) immunodeficient mice.

205 d tumor growth in immunocompetent but not in immunodeficient mice.

206 nd in activated human T cells transferred to immunodeficient mice.

207 ng and developing proliferation advantage in immunodeficient mice.

208 m the corrected cell clone were grafted onto immunodeficient mice.

209 rowth in human lung carcinoma xenografted in immunodeficient mice.

210 in soft agar and rapidly produced tumors in immunodeficient mice.

211 of samples that would not engraft the BM of immunodeficient mice.

212 and attenuated xenograft tumor formation in immunodeficient mice.

213 angiogenesis and peritoneal tumor growth in immunodeficient mice.

214 ntial of BCP-ALL cells xenotransplanted into immunodeficient mice.

215 term engraftment of human CML CD34+ cells in immunodeficient mice.

216 anoid culture before being transplanted into immunodeficient mice.

217 o HSC cells in their ability to reconstitute immunodeficient mice; however, dnMaml-transduced HSCs we

218 d/or injected into flanks of severe combined immunodeficient mice; xenograft tumor growth and metasta

219 nsfer to Prkdc(scid)-mutant (severe combined immunodeficient) mice.

220 such cells through immunocompetent (but not immunodeficient) mice.

221 emination defect in immunocompetent, but not immunodeficient, mice, and the defect was found to resol

222 east 4 to 6 weeks after transplantation into immunodeficient mouse hosts.

223 ng was evaluated both in vitro and within an immunodeficient mouse model of autologous sarcoma.

224 cells and promotes osteolysis in vivo in an immunodeficient mouse model of bone metastasis through u

225 of a DMD patient (mdcs) transplanted into an immunodeficient mouse model of DMD, we report that two n

226 In an immunodeficient mouse model of dormant breast cancer, th

227 xenogeneic nonobese diabetic/severe combined immunodeficient mouse model.

228 ost-labeling both in vitro and in vivo in an immunodeficient mouse model.

229 duce functional improvement in an all-female immunodeficient mouse model.

230 We describe two novel immunodeficient mouse models of hyperlipidemia (Rag1(-/)

231 The development of highly immunodeficient mouse strains into which human immune sy

232 islets by [(11)C]AZ12204657 was shown in the immunodeficient mouse transplantation model.

233 rial transfer was observed in vivo in an NSG immunodeficient mouse xenograft model and also occurred

234 ve activities in TSC2-deficient cells and an immunodeficient mouse xenograft model of lymphangioleiom

235 t also inhibited tumor growth in vivo in two immunodeficient mouse xenograft models.

236 Immunodeficient mouse-human chimeras provide a powerful

237 Immunodeficient MyD88-knockout mice infected with S. aur

238 ge in competition experiments carried out in immunodeficient MyD88-knockout mice or in neutrophil-dep

239 lting in the diagnosis of a higher number of immunodeficient newborns than previously estimated.

240 nes, and human B cell activation factor into immunodeficient NOD scid gamma (NSG) mice by the use of

241 ns of mice (C57BL/6, BALB/c, or the severely immunodeficient NOD-scid,gammac(null) [NSG]).

242 or spots, and tumor burden in BLCL-engrafted immunodeficient NOD-SCID/Il2rg(-/-) mice.

243 D19(+) B cell population after transfer into immunodeficient NOD.Cg-Prkdc(scid) Il2rg(tm1wjl)/SxJ neo

244 Immunodeficient NOD.Cg-Prkdc(scid)IL2rg(tm1Wjl)(NSG) mic

245 ic application of the Fcmu-drug conjugate in immunodeficient NOD/SCID/IL-2Rgamma(null) (NSG) mice eng

246 abeled cell sorting and transplantation into immunodeficient NOD/SCID/interleukin 2 receptor gamma ch

247 cidence in nonobese diabetic/severe combined immunodeficient (NOD/SCID) Ilgamma2(null) mice and deepe

248 h CML by using xenotransplant experiments in immunodeficient NOG mice, and we showed that engraftment

249 r (control) and subcutaneously injected into immunodeficient NSG mice.

250 166(-) cells to the bone marrow of engrafted immunodeficient NSG mice.

251 S/G2-phase human HSCs after engraftment into immunodeficient (NSG) mice, a phenotype that is associat

252 s (HSPCs) expressing MLL-AF9 or MLL-Af4 into immunodeficient NSGS mice, which strongly promote myeloi

253 In immunodeficient or chemotherapy-treated mice, the intest

254 None of these children were considered immunodeficient or had an increased frequency of infecti

255 hese recommendations address the concern for immunodeficient patients acquiring infections from healt

256 is usually safe but cannot be given to many immunodeficient patients and retains the capacity to est

257 viral or bacterial vaccines can be given to immunodeficient patients and the growing neglect of soci

258 Immunodeficient patients are particularly vulnerable to

259 or vaccine-derived diseases being spread to immunodeficient patients at risk for close-contact sprea

260 effort to evaluate serum from autoimmune and immunodeficient patients for Abs against cytokines, chem

261 rvations support the concept that some DOCK8-immunodeficient patients have mutable mosaic genomes tha

262 to incriminate single-gene inborn errors in immunodeficient patients results from the relative ease

263 Immunodeficient patients who have received therapeutic h

264 nalizes more than 60 mutations identified in immunodeficient patients, as well as a large body of gen

265 ines are essential for disease prevention in immunodeficient patients, just as they are for healthy s

266 unity is important for clinical decisions in immunodeficient patients.

267 methicillin-resistant S. aureus infection in immunodeficient patients.

268 e etiology of chronic meningoencephalitis in immunodeficient patients.

269 excretion of vaccine-derived polioviruses by immunodeficient persons (iVDPV) presents a personal risk

270 iated NOD2 mutations could cause a primarily immunodeficient phenotype by selectively impairing TLR4-

271 ict B cell signaling could contribute to the immunodeficient phenotype of these mice and is consisten

272 ous or compound heterozygous state cause the immunodeficient phenotype.

273 tcome relative to mice, we worked to develop immunodeficient rabbits by CRISPR/Cas9.

274 icient rabbits, as well as multigenic mutant immunodeficient rabbits have been produced.

275 of SGM (e.g. FOXN1, RAG2, IL2RG, and PRKDC) immunodeficient rabbits, as well as multigenic mutant im

276 By serially transplanting hyperplasias into immunodeficient rag1 mutant zebrafish, we succeeded in l

277 verexpress H-2K(b) in muscle were bred to an immunodeficient Rag2(-/-) background.

278 In contrast, thymi of immunodeficient Rag2(-/-) mice exhibit only ~20 small, u

279 doptive transfer of TRAIL-null NK cells into immunodeficient RAG2/common gamma-null mice was associat

280 vertheless, when adoptively transferred into immunodeficient Rai(+/+) mice, these cells promoted a mo

281 nto neural stem cells and grafted into adult immunodeficient rats after spinal cord injury.

282 SCs that were implanted into sites of SCI in immunodeficient rats over a period of 1.5 years.

283 nctive B cell progeny when transplanted into immunodeficient recipients, supporting a two-pathway mod

284 ma cells were implanted into the striatum of immunodeficient RNU rats.

285 which is nearly completely abolished in the immunodeficient SCID/beige (bg) variant.

286 of MEDI-575 in tumor-bearing severe combined immunodeficient (SCID) mice and in genetically altered S

287 after 24 serial passages in severe combined immunodeficient (SCID) mice caused severe disease when a

288 ocytes were transferred into severe combined immunodeficient (SCID) mice to induce ITP.

289 Severe combined immunodeficient (SCID) mice were infected and treated wi

290 bjected to DNFB-induced CHS, severe combined immunodeficient (SCID) mice were injected with CD4(+) T

291 ction of PA in tumor-bearing severe combined immunodeficient (SCID) mice.

292 tumor growth in the lung of severe combined immunodeficient (SCID) mice.

293 RAG1-mutants from severe combined immunodeficient (SCID) patient cells showed a failure to

294 lium-free mammary fat pad of severe combined immunodeficient (SCID)/Beige and nonobese diabetic (NOD)

295 an be enriched in vivo, in a severe combined immunodeficient (SCID)/beige mouse host.

296 on as well as the maximum-tolerated dose for immunodeficient strains.

297 nd cellular vaccine responses in healthy and immunodeficient subjects and how that knowledge can then

298 nhibition, we performed xenograft studies in immunodeficient Tg2(-/-) mice.

299 elicited opposite effects on tumor growth in immunodeficient tumor-bearing mice.

300 accharides, is severely impaired in X-linked immunodeficient (XID) mice.